Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of …
E Arbelo, A Protonotarios, JR Gimeno… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …
N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association …
Writing Committee Members, SS Virani… - Journal of the American …, 2023 - jacc.org
Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
PE Stevens, SB Ahmed, JJ Carrero… - Kidney …, 2024 - kidney-international.org
This article is published as part of a supplement sponsored by Kidney Disease: Improving
Global Outcomes (KDIGO). The opinions or views expressed in this supplement are those of …
Global Outcomes (KDIGO). The opinions or views expressed in this supplement are those of …
2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the …
C Vrints, F Andreotti, KC Koskinas… - European heart …, 2024 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
Monitoring blood pressure and cardiac function without positioning via a deep learning–assisted strain sensor array
Continuous and reliable monitoring of blood pressure and cardiac function is of great
importance for diagnosing and preventing cardiovascular diseases. However, existing …
importance for diagnosing and preventing cardiovascular diseases. However, existing …
A placebo-controlled trial of percutaneous coronary intervention for stable angina
CA Rajkumar, MJ Foley, F Ahmed-Jushuf… - … England Journal of …, 2023 - Mass Medical Soc
Background Percutaneous coronary intervention (PCI) is frequently performed to reduce the
symptoms of stable angina. Whether PCI relieves angina more than a placebo procedure in …
symptoms of stable angina. Whether PCI relieves angina more than a placebo procedure in …
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …
AR Lyon, T López-Fernández, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …
that, unless otherwise provided for by national regulations, offlabel use of medication should …
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular …
S Halvorsen, J Mehilli, S Cassese, TS Hall… - European heart …, 2022 - academic.oup.com
Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …
evidence shows that it can be considered medically appropriate to a given condition and if …
Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis
GO Dibben, J Faulkner, N Oldridge, K Rees… - European heart …, 2023 - academic.oup.com
Aims Coronary heart disease is the most common reason for referral to exercise-based
cardiac rehabilitation (CR) globally. However, the generalizability of previous meta-analyses …
cardiac rehabilitation (CR) globally. However, the generalizability of previous meta-analyses …